Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.
2.

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW.

Nat Med. 2005 Jul;11(7):786-90. Epub 2005 Jun 5.

PMID:
15937495
3.

Potential mammalian filovirus reservoirs.

Peterson AT, Carroll DS, Mills JN, Johnson KM.

Emerg Infect Dis. 2004 Dec;10(12):2073-81.

4.

Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection.

Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S.

Vaccine. 2004 Sep 3;22(25-26):3495-502.

PMID:
15308377
5.

Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics.

Watanabe S, Watanabe T, Noda T, Takada A, Feldmann H, Jasenosky LD, Kawaoka Y.

J Virol. 2004 Jan;78(2):999-1005.

6.

Ebola virus-like particles protect from lethal Ebola virus infection.

Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15889-94. Epub 2003 Dec 12.

7.

Ebola virus pathogenesis: implications for vaccines and therapies.

Sullivan N, Yang ZY, Nabel GJ.

J Virol. 2003 Sep;77(18):9733-7. Review. No abstract available.

8.

Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.

Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D, Bray M, Ruff A, Ivins B, Bassett A, Rossi C, Schmaljohn C.

Vaccine. 2003 Sep 8;21(25-26):4071-80.

PMID:
12922144
9.

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.

Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ.

Nature. 2003 Aug 7;424(6949):681-4.

PMID:
12904795
10.

Vaccine research efforts for filoviruses.

Hart MK.

Int J Parasitol. 2003 May;33(5-6):583-95. Review.

PMID:
12782057
11.

Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs.

Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, Saikh KU, Heidebrink KD, Jahrling PB, Ulrich RG, Schmaljohn CS.

Virus Res. 2003 Apr;92(2):187-93.

PMID:
12686428
12.

Improving the transcriptional regulation of genes delivered by adenovirus vectors.

Rubinchik S, Woraratanadharm J, Schepp J, Dong JY.

Methods Mol Med. 2003;76:167-99. No abstract available.

PMID:
12526164
13.

Evaluation in nonhuman primates of vaccines against Ebola virus.

Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB.

Emerg Infect Dis. 2002 May;8(5):503-7.

14.

Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes.

Rubinchik S, Norris JS, Dong JY.

Methods Enzymol. 2002;346:529-47. No abstract available.

PMID:
11883089
15.

A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.

Rubinchik S, Wang D, Yu H, Fan F, Luo M, Norris JS, Dong JY.

Mol Ther. 2001 Nov;4(5):416-26.

16.
17.

Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.

Wilson JA, Bray M, Bakken R, Hart MK.

Virology. 2001 Aug 1;286(2):384-90.

18.
19.

Development of a preventive vaccine for Ebola virus infection in primates.

Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ.

Nature. 2000 Nov 30;408(6812):605-9.

PMID:
11117750
20.

Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.

Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF.

Vaccine. 2000 Aug 15;19(1):142-53.

PMID:
10924796

Supplemental Content

Support Center